JP6949832B2 - タンパク質コンジュゲート - Google Patents
タンパク質コンジュゲート Download PDFInfo
- Publication number
- JP6949832B2 JP6949832B2 JP2018516719A JP2018516719A JP6949832B2 JP 6949832 B2 JP6949832 B2 JP 6949832B2 JP 2018516719 A JP2018516719 A JP 2018516719A JP 2018516719 A JP2018516719 A JP 2018516719A JP 6949832 B2 JP6949832 B2 JP 6949832B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- conjugate
- linker
- mmol
- dmf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- WVEJOAFASFZJGN-UHFFFAOYSA-N OC(CC(CCCCNC(N(CCNC(CCl)=O)CCNC(CCl)=O)=O)NC(COCCOCCNC(CBr)=O)=O)=O Chemical compound OC(CC(CCCCNC(N(CCNC(CCl)=O)CCNC(CCl)=O)=O)NC(COCCOCCNC(CBr)=O)=O)=O WVEJOAFASFZJGN-UHFFFAOYSA-N 0.000 description 1
- BRZARVOXMUDVKR-OZAIVSQSSA-N OC(CCC(C(NCCN(CCNC(CCl)=O)C(CCl)=O)=O)NC(COCCOCCNC(CC[C@H](C(O)=O)NC(COCCOCCNC(CBr)=O)=O)=O)=O)=O Chemical compound OC(CCC(C(NCCN(CCNC(CCl)=O)C(CCl)=O)=O)NC(COCCOCCNC(CC[C@H](C(O)=O)NC(COCCOCCNC(CBr)=O)=O)=O)=O)=O BRZARVOXMUDVKR-OZAIVSQSSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15187937 | 2015-10-01 | ||
| EP15187937.6 | 2015-10-01 | ||
| PCT/EP2016/073470 WO2017055582A1 (en) | 2015-10-01 | 2016-09-30 | Protein conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535195A JP2018535195A (ja) | 2018-11-29 |
| JP2018535195A5 JP2018535195A5 (cg-RX-API-DMAC7.html) | 2019-11-07 |
| JP6949832B2 true JP6949832B2 (ja) | 2021-10-13 |
Family
ID=54252136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516719A Expired - Fee Related JP6949832B2 (ja) | 2015-10-01 | 2016-09-30 | タンパク質コンジュゲート |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11292825B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3355931B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6949832B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108136043B (cg-RX-API-DMAC7.html) |
| ES (1) | ES2985999T3 (cg-RX-API-DMAC7.html) |
| MA (1) | MA43348A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017055582A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3303380B1 (en) | 2015-06-02 | 2020-01-15 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
| WO2017055582A1 (en) | 2015-10-01 | 2017-04-06 | Novo Nordisk A/S | Protein conjugates |
| EP3532497B1 (en) * | 2016-10-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| US10864279B2 (en) * | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
| JP2020513019A (ja) * | 2017-04-05 | 2020-04-30 | ノヴォ ノルディスク アー/エス | オリゴマー伸長インスリン−Fcコンジュゲート |
| MA68842B1 (fr) * | 2017-08-04 | 2025-01-31 | Amgen Inc. | Procédé de conjugaison de cys-mabs |
| EP4241789A4 (en) * | 2020-12-08 | 2025-04-02 | Nona Biosciences (Shanghai) Co., Ltd. | Protein-drug conjugate and site-specific conjugation method |
| CN113024669B (zh) * | 2021-03-12 | 2022-06-14 | 北京华科泰生物技术股份有限公司 | 含氨基或羧基基团物质标记的rbp抗体、人rbp免疫层析检测试剂盒及其制备方法 |
| CN115819611B (zh) * | 2021-12-30 | 2024-05-28 | 君合盟生物制药(杭州)有限公司 | 生长激素融合蛋白及其制备方法和用途 |
| CN115845032B (zh) * | 2022-10-28 | 2026-02-06 | 深圳科兴药业有限公司 | 生长激素fc融合蛋白注射液及其用途 |
| WO2025184552A2 (en) * | 2024-03-01 | 2025-09-04 | The Scripps Research Institute | Dual gip/glp-1 peptide conjugates and methods of use |
| US20260158159A1 (en) * | 2024-07-24 | 2026-06-11 | Eli Lilly And Company | Fc-ACYLATED POLYPEPTIDE CONJUGATES |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE286509C (cg-RX-API-DMAC7.html) | ||||
| DE257197C (cg-RX-API-DMAC7.html) | ||||
| US3914252A (en) | 1971-03-15 | 1975-10-21 | Continental Oil Co | Preparation of N-iodocompounds |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| ATE455171T1 (de) | 1995-09-21 | 2010-01-15 | Genentech Inc | Varianten des menschlichen wachstumshormons |
| WO1998022577A1 (en) | 1996-11-15 | 1998-05-28 | Maria Grazia Masucci | Fusion proteins having increased half-lives |
| ATE375363T1 (de) | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
| ATE407697T1 (de) | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| US7608681B2 (en) | 1999-12-24 | 2009-10-27 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| JP2004524020A (ja) | 2001-01-11 | 2004-08-12 | マキシゲン・エイピーエス | 改良された成長ホルモン分子 |
| US20060183197A1 (en) | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
| US20020169125A1 (en) | 2001-03-21 | 2002-11-14 | Cell Therapeutics, Inc. | Recombinant production of polyanionic polymers and uses thereof |
| AU2002341215A1 (en) | 2001-11-12 | 2003-05-26 | University Of Wales College Of Medicine | Growth hormone variations in humans and their uses |
| GB2384001B (en) | 2001-12-14 | 2004-02-04 | Asterion Ltd | Chimeric growth hormone-growth hormone receptor proteins |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| BRPI0406605B8 (pt) | 2003-11-13 | 2021-05-25 | Hanmi Holdings Co Ltd | conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo |
| EP2033662B1 (en) | 2004-01-21 | 2012-10-17 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
| KR100594607B1 (ko) | 2004-11-03 | 2006-06-30 | 재단법인서울대학교산학협력재단 | 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법 |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| CA2595695A1 (en) | 2005-01-25 | 2006-08-03 | Cell Therapeutics, Inc. | Biologically active protein conjugates comprising (nn[s/t]) peptide repeats and having increased plasma half-life |
| US20090036353A1 (en) | 2005-01-27 | 2009-02-05 | Novo Nordisk A/S | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers |
| MX2007009906A (es) | 2005-02-16 | 2007-09-25 | Novo Nordisk As | Derivados de agentes insulinotropicos conjugados con polimeros ramificados estructuralmente bien definidos. |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
| CA2606102C (en) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| US8492129B2 (en) | 2005-12-12 | 2013-07-23 | Innova Biosciences, Ltd. | Production of conjugates |
| EP1971355B1 (en) | 2005-12-20 | 2020-03-11 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| CA2644712C (en) | 2006-03-06 | 2016-09-13 | Amunix, Inc. | Unstructured recombinant polymers and uses thereof |
| WO2008019368A2 (en) | 2006-08-07 | 2008-02-14 | Teva Biopharmaceuticals Usa, Inc. | Albumin-insulin fusion proteins |
| WO2008052108A2 (en) | 2006-10-26 | 2008-05-02 | Centocor Ortho Biotech Inc. | Methods for use in human-adapting monoclonal antibodies |
| WO2008049711A1 (en) | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
| US20100303723A1 (en) | 2006-11-20 | 2010-12-02 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| KR20080095141A (ko) | 2007-04-23 | 2008-10-28 | 포항공과대학교 산학협력단 | 인간 알부민 링커를 통하여 면역글로불린의 Fc에 결합된생리학적 활성 폴리펩티드의 융합 폴리펩티드, 및 이의제조방법 |
| CN101687933B (zh) | 2007-05-30 | 2015-11-25 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| AU2008255352B2 (en) | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| WO2009015345A1 (en) | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
| CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| JP5703020B2 (ja) | 2007-08-24 | 2015-04-15 | ノボ ノルディスク ヘルス ケア アーゲー | タンパク質を選択的に修飾するための組成物と方法 |
| WO2009053368A1 (en) | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Single ifn-beta fused to a mutated igg fc fragment |
| CN106822891A (zh) | 2008-06-20 | 2017-06-13 | 诺华公司 | 具有降低的聚集的免疫球蛋白 |
| WO2010001196A1 (en) | 2008-07-02 | 2010-01-07 | Koninklijke Philips Electronics N.V. | V-spring configuration and end attachment assemblies therefor for use in a personal care appliance |
| EP2300501B1 (en) * | 2008-07-23 | 2014-08-20 | Hanmi Science Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
| JP5808671B2 (ja) | 2008-11-10 | 2015-11-10 | ノヴォ ノルディスク アー/エス | 機能グループii莢膜遺伝子クラスターを有しないe.colibl21株 |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| KR20120092611A (ko) | 2009-09-30 | 2012-08-21 | 글락소 그룹 리미티드 | 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트 |
| EP2494061B1 (en) | 2009-10-29 | 2017-01-25 | Janssen Biotech, Inc. | Antibody glycosylation variants |
| US8637637B2 (en) | 2010-01-12 | 2014-01-28 | Bill Nai-Chau Sun | Fc fusion proteins of human growth hormone |
| RU2012134974A (ru) | 2010-01-22 | 2014-02-27 | Ново Нордиск Хелс Кеа Аг | Стабилизированное соединение гормона роста |
| PL2525834T3 (pl) | 2010-01-22 | 2020-10-19 | Novo Nordisk Health Care Ag | Hormony wzrostu o przedłużonej skuteczności in-vivo |
| AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| DK2571510T3 (en) | 2010-05-21 | 2018-11-19 | Xl Protein Gmbh | BIOSYNTHETIC PROLIN / ALANIN-RANDOM COIL POLYPEPTIDES AND THEIR APPLICATIONS |
| KR101337797B1 (ko) | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
| CN103269720A (zh) | 2010-07-22 | 2013-08-28 | 诺沃—诺迪斯克保健股份有限公司 | 生长激素缀合物 |
| EP2694528A1 (en) | 2011-04-05 | 2014-02-12 | Martin-Protean, LLC | Isolation of cysteine containing peptides |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| CN104302408B (zh) * | 2012-02-27 | 2016-12-14 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| US9545449B2 (en) | 2012-05-11 | 2017-01-17 | Advanced Proteone Therapeutics Inc. | Site-specific labeling and targeted delivery of proteins for the treatment of cancer |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| US20160115216A1 (en) | 2013-06-07 | 2016-04-28 | Novo Nordisk A/S | Method for Making Mature Insulin Polypeptides |
| WO2015038938A1 (en) | 2013-09-13 | 2015-03-19 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| ES2729643T3 (es) | 2013-11-26 | 2019-11-05 | Novartis Ag | Métodos para la conjugación de oxima con polipéptidos modificados con cetona |
| EP4053560A1 (en) | 2013-11-26 | 2022-09-07 | The Brigham and Women's Hospital, Inc. | Compositions and methods for modulating an immune response |
| CN106068274A (zh) | 2014-03-05 | 2016-11-02 | Ucb生物制药私人有限公司 | 多聚体Fc蛋白 |
| US11279771B2 (en) | 2014-09-17 | 2022-03-22 | Novo Nordisk A/S | Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161) |
| WO2016133372A2 (ko) | 2015-02-17 | 2016-08-25 | 한미약품 주식회사 | 지속형 인슐린 또는 이의 아날로그 결합체 |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| EP3303380B1 (en) | 2015-06-02 | 2020-01-15 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
| ES2907651T3 (es) | 2015-08-14 | 2022-04-25 | Remegen Biosciences Inc | Enlazadores covalentes en conjugados de anticuerpo-fármaco y métodos para obtener y usar los mismos |
| WO2017055582A1 (en) | 2015-10-01 | 2017-04-06 | Novo Nordisk A/S | Protein conjugates |
| JP2020513019A (ja) | 2017-04-05 | 2020-04-30 | ノヴォ ノルディスク アー/エス | オリゴマー伸長インスリン−Fcコンジュゲート |
| US20210393745A1 (en) | 2018-10-10 | 2021-12-23 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates and their medical use |
-
2016
- 2016-09-30 WO PCT/EP2016/073470 patent/WO2017055582A1/en not_active Ceased
- 2016-09-30 US US15/763,857 patent/US11292825B2/en not_active Expired - Fee Related
- 2016-09-30 ES ES16775707T patent/ES2985999T3/es active Active
- 2016-09-30 EP EP16775707.9A patent/EP3355931B1/en not_active Revoked
- 2016-09-30 CN CN201680056457.1A patent/CN108136043B/zh active Active
- 2016-09-30 MA MA43348A patent/MA43348A/fr unknown
- 2016-09-30 JP JP2018516719A patent/JP6949832B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN108136043A (zh) | 2018-06-08 |
| ES2985999T3 (es) | 2024-11-08 |
| JP2018535195A (ja) | 2018-11-29 |
| WO2017055582A1 (en) | 2017-04-06 |
| US11292825B2 (en) | 2022-04-05 |
| CN108136043B (zh) | 2022-09-06 |
| EP3355931A1 (en) | 2018-08-08 |
| EP3355931B1 (en) | 2024-06-26 |
| MA43348A (fr) | 2018-08-08 |
| US20180282387A1 (en) | 2018-10-04 |
| EP3355931C0 (en) | 2024-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108136043B (zh) | 蛋白质缀合物 | |
| JP7754361B2 (ja) | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | |
| JP2025023052A (ja) | 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | |
| CN104066438B (zh) | 抗糖尿病化合物 | |
| JP6745218B2 (ja) | ヒドラジニル−ピロロ化合物及び複合体を生成するための方法 | |
| KR20210020015A (ko) | 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염 | |
| JP6727210B2 (ja) | Fgf21誘導体及びその使用 | |
| RU2598273C2 (ru) | Производные инсулина, содержащие дополнительные дисульфидные связи | |
| JP2012521360A (ja) | Kv1.3の選択的かつ強力なペプチド阻害剤 | |
| JP2020114234A (ja) | Xten共役組成物およびそれを製造する方法 | |
| BRPI0607248A2 (pt) | conjugado de um polipeptìdeo e um oligossacarìdeo, composição farmacêutica, uso do conjugado, e, processo para a preparação de um conjugado | |
| TW201446792A (zh) | Nav1.7之強效及選擇性抑制劑 | |
| US20210393745A1 (en) | Oligomer extended insulin-fc conjugates and their medical use | |
| JP2025124732A (ja) | 化合物またはその塩、およびそれらにより得られる抗体 | |
| KR20230133289A (ko) | 화합물 또는 이의 염, 및 이들에 의해 얻어지는 항체 | |
| US11884711B2 (en) | Fusion proteins of GDF15 and use thereof | |
| JP7823234B2 (ja) | 長時間作用型成長ホルモン受容体拮抗薬およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190926 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190926 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200923 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201222 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210616 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210616 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210624 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210628 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210830 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210922 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6949832 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |